Fig. 2From: Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapyReceiver-operator characteristic (ROC) analyses to describe specificities and sensitivities in distinguishing active from not active RA of calprotectin (a, d), ESR (b, e), and CRP (c, f) in tocilizumab (TCZ)-treated RA patients (a–c) and in tumor necrosis factor alpha-inhibitor (TNFi)-treated (d–f) RA patientsBack to article page